Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232726 · ClinicalTrials.gov registry record · Phase 2
Clinical Study of Previously Untreated Patients With Malignant Melanoma
A Phase 2 study, sponsored by Clavis Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00232726: Completed Phase 2 study, sponsored by Clavis Pharma.
NCT00232726 is a Phase 2 study that has completed, run by Clavis Pharma. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232726, a Phase 2 study, has completed, sponsored by Clavis Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.
Interventions
- DRUG CP-4055 (ELACYT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00232726 record still lists
NCT00232726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which CP-4055 (ELACYT) is the first listed.
NCT00232726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00232726 about?
NCT00232726 is a clinical study titled "Clinical Study of Previously Untreated Patients With Malignant Melanoma". Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.
What is the current status of trial NCT00232726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2005-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00232726?
The interventions under investigation include: CP-4055 (ELACYT) (DRUG).
Who is sponsoring clinical trial NCT00232726?
This trial is sponsored by Clavis Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00232726's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia